Table 2. Demographic, tumor and treatment characteristics of patients with locally advanced, non-metastatic disease treated with gemcitabine and capecitabine (gem-cap) as stratified by adjuvant versus systemic therapy.
| Characteristic | Systemic, n (%) | Adjuvant, n (%) | Overall, n (%) |
|---|---|---|---|
| Overall (n) | 18 (42.9) | 24 (57.1) | 42 (100.0) |
| Age (mean/Std) | 69.6/9.5 | 60.1/8.23 | 64.3/9.9 |
| Gender | |||
| Male | 7 (38.9) | 8 (33.3) | 15 (35.7) |
| Female | 11 (61.1) | 16 (66.7) | 27 (64.3) |
| ECOG | |||
| 0 | 14 (77.8) | 17 (70.8) | 31 (73.8) |
| 1 | 4 (22.2) | 7 (29.2) | 11 (26.2) |
| ASA | |||
| 1 | 4 (22.2) | 7 (29.2) | 11 (26.2) |
| 2 | 10 (55.6) | 14 (58.3) | 24 (57.1) |
| 3 | 4 (22.2) | 3 (12.5) | 7 (16.7) |
| CA19-9 serum level, mean/Std (units/mL) | 564.4/1,380.2 | 535.7/1,007.5 | 549.0/1,179.1 |
| Total bilirubin serum level, mean/Std (µmol/L) | 3.5/5.4 | 2.8/4.2 | 3.1/4.7 |
| Type of cancer | |||
| IHCC | 12 (66.7) | 4 (16.7) | 16 (38.1) |
| EHCC | 2 (11.1) | 9 (37.5) | 11 (26.2) |
| GBC | 4 (22.2) | 11 (45.8) | 15 (35.7) |
| Grade | |||
| Grade I/II | – | 16 (66.7) | 22 (51.2) |
| Grade III/IV | – | 8 (33.3) | 14 (32.6) |
| Path stage | |||
| I | – | 1 (4.2) | – |
| II | – | 10 (41.7) | – |
| III | – | 13 (54.1) | – |
| Type of surgery | |||
| Cholecystectomy | – | 9 (37.5) | – |
| Hepatectomy | – | 8 (33.3) | – |
| Whipple | – | 7 (29.2) | – |
| Adjuvant radiation | |||
| No | – | 11 (45.8) | – |
| Yes | – | 13 (54.2) | – |
| Margins | |||
| Negative | – | 16 (66.7) | – |
| Positive | – | 8 (33.3) | – |
| Number lymph nodes positive (mean/Std) | – | 0.76/0.90 | – |
| Number lymph nodes examined (mean/Std) | – | 9.83/8.89 | – |
| Number gem-cap cycles (mean/Std) | – | 6.35/2.17 | – |
gem-cap, gemcitabine and capecitabine; Std, standard deviation.